The Wall Street Journal is reporting that the Genentech board is close to accepting a $46.7 billion offer from Swiss pharmaceutical giant Roche.

If the board accepts the deal, it would end months of uncertainty regarding the San Francisco-based biotech, which has a 500-employee plant in Oceanside. The newest offer equates to $95 a share, and is more than $4 billion more than the hostile bid rejected by the Genentech board last month.

However the price would be well below the original $112-a-share demand by the board. In September, we wrote about how the local employees might be affected by a Roche takeover.


Leave a comment

We expect all commenters to be constructive and civil. We reserve the right to delete comments without explanation. You are welcome to flag comments to us. You are welcome to submit an opinion piece for our editors to review.

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.